RAC (ASX) Ann: Race raises $29.7 million in oversubscribed SPP

Originally posted by Aqua65: ↑

I got scaled back 50% also.
Two entities - myself and smsf. So I hope this was the reason.

Scale back was significant clearly and not personal.
Was disappointed as endeavoured to participate fully with concern especially for how the SPP might have resulted, and to fund quickly cost also.
Sold down other shares basically through these weeks.
But loyalty is high to Race Oncology which is my no 1 stock and investment .

Held and bought significantly over some years now.

I was incredibly happy about shareholders efforts with the result this morning! ~ so much so that I bought the open and got filled for full order in the first hour.
Before I had any idea of SPP results at all.

I have pulled out all stops try support momentum on perfect news a number of times through time, not to my advantage in terms of picking price but to also absorb volume, & support shareprice against the Bots and parcels of selling which occur.

RAC deserves to be much higher market cap.

Also I do not understand Smouldering psyche.
I can’t not care.
Never could not care.
If you don’t care about what you are invested in or uncertain that on path to success in aims and holding valuable assets, or don’t believe in abilities of the management and trust them to execute — your conviction won’t be there.

I liked Phil saying that J & J have overarching philosophy that you look for the best outcomes and care for the patients - and follow this as goal always.
*Best treatments evolve as result.

Many of us here are health professionals.
You don’t ever think of the money though it got to be fair for the employing entity and pay costs, while being in absolute best interests of the patient while trying to save them money and ordeal as much as possible, no 1 looking after them and treating their condition, all in consultation with them.
Patient has to understand what happening and want treatment with full informed consent.

I investigate everything I can re bisantrene and have now for more than several years.
I realised very much early on -It was an absolute travesty, though the ways of corporate world back in time and what the takeover entities could do, but limited budgets & debts of the US manufacturing arm partner of Lederle , lead to loss of a very useful oncology drug —which Zantrene is!

Zantrene deserves to be brought into use.

Today in my city women received Doxyrubicin at the main hospital for their breast cancer treatment.
The oncology nurses and doctor know as they administering that heart damage can result .
Dear old friend and colleague who also participated in the SPP lost his wife to a dire renal cancer. In the final attempts in treatment to save her when she seriously relapsed- he remembers and has said so many times he recalls the oncologist saying “she can only have a little bit more “.
Beyond that - hopeless, end of the road was reached.
Zantrene may well have made the difference and prevented the heroic second surgeries attempt and suffering all to no avail which she endured.

Lady who cut my hair tonight has her dad in hospital here with a central line inserted into his chest today coincidently.
For his chemo. Pancreatic cancer.
He won’t be here in the next years.
My parent, husband of dear friend who saw today - also sometime won’t be here in the next years. (Prostate, & Renal cancers )

The FTO inhibition abilities of Zantrene is extremely important to me.
Explains so much. In the development of dire renal, prostate, and certainly breast cancer and AML which Zantrene was fully approved for after a number of trials including 2 phase 3 trials , in France back in time.

I really believe a tendency to over- expression of FTO will be associated with many more disease conditions than currently envisaged- including many dire cancers inc breast and ovarian + R/R AML which Zantrene previously approved for in France.

All the best to all holders & todays SPP result was remarkable.
In hindsight could have been good if was closed early but Dr T has addressed that was not fully subscribed mid last week.
Take care all. It has been a very big year for everyone though we very lucky mostly here in Oz.

Expand

Thank you, Aqua

No.	Vol.	Price($)
1	500	$1.53

No.

Vol.

Price($)

500

$1.53

Price($)	Vol.	No.
$1.56	1400	1

Price($)

Vol.

No.

$1.56

1400

No.	Vol.	Price($)
1	500	1.525
1	828	1.505
2	4000	1.490
1	38500	1.480
3	22244	1.450

No.

Vol.

Price($)

500

1.525

828

1.505

4000

1.490

38500

1.480

22244

1.450

Price($)	Vol.	No.
1.555	1400	1
1.640	1000	1
1.650	14314	2
1.690	585	1
1.745	12000	1

Price($)

Vol.

No.

1.555

1400

1.640

1000

1.650

14314

1.690

585

1.745

12000

(20min delay)
Last $1.54		Change -0.015(0.97%)		Mkt cap ! $261.5M

Open	High	Low	Value	Volume
$1.55	$1.55	$1.50	$111.4K	73.35K

Thank you, Aqua

GreenX picks up prospective copper project in Germany

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Westgold sets its sights on top five producer status through merger with Karora

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Is oil undervalued?

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Venture to sniff out high-grade REE targets at Jupiter project, WA

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thank you, Aqua

Top Stories

GreenX picks up prospective copper project in Germany

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Westgold sets its sights on top five producer status through merger with Karora

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Is oil undervalued?

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Venture to sniff out high-grade REE targets at Jupiter project, WA

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News